QIAGEN N.V. (QGEN)
Here's Why Qiagen (QGEN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
QGEN Stock Rises in After Market Following Partnership With Incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Should You Add QIAGEN Stock to Your Portfolio for Now?
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Here's Why Qiagen (QGEN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
QGEN Stock Might Gain Following New Partnership With ID Solutions
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Qiagen (QGEN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential
QGEN has a relatively well-diversified portfolio across four segments on Sample Technologies, PCR/NA Amplification, Genomics/NGS, and Diagnostic Solutions. Their QIAstat-Dx's multiplex syndromic panels and QuantiFERON TB tests drive double-digit growth. Plus, QGEN seems to have a good competitive position across several niches. Also, QGEN's recent acquisition of Genoox and its AI-powered Franklin software expands their clinical bioinformatics capabilities for scalable genomic interpretation.
